Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
| Autor: | Mili Kapoor, Chris M. Pillar, Quinlyn A. Soltow, Molly K. Moloney, Karen Joy Shaw |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pharmacology
0303 health sciences education.field_of_study biology 030306 microbiology Mutant Population biology.organism_classification Corpus albicans Microbiology 03 medical and health sciences chemistry.chemical_compound Infectious Diseases chemistry Serial passage Amphotericin B medicine Pharmacology (medical) Caspofungin education Candida albicans Fluconazole 030304 developmental biology medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 64 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fungal infections. We determined that the median frequencies of spontaneous mutations conferring reduced susceptibility to MGX in Candida albicans, C. glabrata, and C. parapsilosis ranged from 3 × 10-8 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|